Clinical trial · no report yet · Phase 2/Phase 3
RINGSIDE
A Study of AL102 in Patients With Progressing Desmoid Tumors
- NCT04871282 ↗
- Active not recruiting
- Immunome, Inc.
- 26 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 14 | |
| Podcasts | 10 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors
- Phase
- Phase 2/Phase 3
- Status
- Active not recruiting
- Conditions
- Desmoid; Desmoid Tumor
- Interventions
- AL102; Placebo
- Arms
- Part A Main Study 1.2 mg daily · Experimental
- Part A Main Study 2 mg Intermittent · Experimental
- Part A Main Study 4 mg Intermittent · Experimental
- Part B AL102 · Experimental
- Part B Placebo · Placebo comparator
- Open Label Extension · Experimental
- Enrollment
- 198
- Primary outcomes
- Part A: Safety and Tolerability - Adverse Events
- Part B: Progression free survival (PFS)
- Sponsor
- Immunome, Inc.
- Start
- Sep 1, 2021
- Primary completion
- Dec 3, 2025
- Results posted
- No
- Registry record
- NCT04871282 · updated Jun 8, 2026